Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep 15;60(3):2201187.
doi: 10.1183/13993003.01187-2022. Print 2022 Sep.

Reply: COVID-19 drug research and the cohort multiple randomised controlled trial design

Raphaël Porcher  1 , Philippe Ravaud  1 , Matthieu Resche-Rigon  2 , Pierre-Louis Tharaux  3 , Xavier Mariette  4 , Olivier Hermine  5   6
Affiliations
Comment

Reply: COVID-19 drug research and the cohort multiple randomised controlled trial design

Raphaël Porcher et al. Eur Respir J. .

Abstract

The use of cohort multiple randomised controlled trials and epidemic crises https://bit.ly/39Obd4N

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: P-L. Tharaux has received honorarium fees for participation on advisory boards for Travere Therapeutics. The remaining authors disclose no potential conflicts of interest.

Comment on

References

    1. Hermine O, Mariette X, Tharaux PL, et al. . Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med 2021; 181: 32–40. doi:10.1001/jamainternmed.2020.6820 - DOI - PMC - PubMed
    1. CORIMUNO-19 Collaborative group . Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med 2021; 9: 295–304. doi:10.1016/S2213-2600(20)30556-7 - DOI - PMC - PubMed
    1. CORIMUNO-19 Collaborative group . Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): an open-label randomised controlled trial. Lancet Rheumatol 2022; 4: e24–e32. doi:10.1016/S2665-9913(21)00315-5 - DOI - PMC - PubMed
    1. Hermine O, Mariette X, Porcher R, et al. . Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. Eur Respir J 2022; 60: 2102523. doi:10.1183/13993003.02523-2021 - DOI - PMC - PubMed
    1. Hermine O, Mariette X, Porcher R, et al. . Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: a randomised clinical trial from the CORIMUNO-19 study group. eClinicalMedicine 2022; 46: 101362. doi:10.1016/j.eclinm.2022.101362 - DOI - PMC - PubMed

Substances